We underscore the critical importance of BCL6 and its associated epigenetic programs in the development of B-cell lymphoma, and discuss avenues for the therapeutic targeting of BCL6 in this context. This evidence concerns the gene BCL6 and B-cell non-Hodgkin lymphoma.